The US Food and Drug Administration’s paediatric advisory committee will meet on 21 June to discuss paediatric-focused safety reviews for 13 drugs, including four proton pump inhibitors1.
The four PPIs are: AstraZeneca’s Nexium (esomeprazole) and Prilosec (omeprazole); Eisai/Johnson & Johnson’s Aciphex (rabeprazole); and Takeda Pharmaceuticals’ Prevacid (lansoprazole)...
Please login to read the full article.